3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
NIH
2
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
pembrolizumab
166
Carboplatin
132
Cisplatin
81
Paclitaxel
78
Gemcitabine
77
Pemetrexed
72
Bevacizumab
63
Docetaxel
54
Fluorouracil
49
Oxaliplatin
48
Dexamethasone
46
durvalumab
43
atezolizumab
39
Leucovorin
39
130-nm albumin-bound paclitaxel
39
Capecitabine
37
Cetuximab
36
Rituximab
35
Nivolumab
35
Fulvestrant
35
Cyclophosphamide
34
Injections
31
venetoclax
29
Prednisone
28
Lenalidomide
28
enzalutamide
27
pomalidomide
25
Letrozole
25
Irinotecan
25
daratumumab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Diphenhydramine
×
30 days
×
Clear all
NCT07570173
2026-05-26
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
340 enrolled
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts